Sunshine Biopharma (SBFM) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Sunshine Biopharma (SBFM) over the last 2 years, with Mar 2025 value amounting to -$0.44.
- Sunshine Biopharma's EPS (Weighted Average and Diluted) rose 78.00% to -$0.44 in Q1 2025 from the same period last year, while for Mar 2025 it was -$102.98, marking a year-over-year decrease of 3.47%. This contributed to the annual value of -$7.32 for FY2024, which is 97.92% up from last year.
- Per Sunshine Biopharma's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.44 for Q1 2025, which was up 85.69% from -$3.08 recorded in Q4 2024.
- In the past 5 years, Sunshine Biopharma's EPS (Weighted Average and Diluted) registered a high of $0.26 during Q4 2021, and its lowest value of -$97.47 during Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$15.82, with a median of -$2 in 2024.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 6,193.06% in 2023, then skyrocketed by 96.84% in 2024.
- Over the past 5 years, Sunshine Biopharma's EPS (Weighted Average and Diluted) (Quarterly) stood at $0.26 in 2021, then crashed by 706.43% to -$1.55 in 2022, then plummeted by 6,193.06% to -$97.47 in 2023, then surged by 96.84% to -$3.08 in 2024, then skyrocketed by 78.00% to -$0.44 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.44 for Q1 2025, versus -$3.08 for Q4 2024 and -$2 for Q1 2024.